Article | February 23, 2022

Why Companies Are Choosing To Manufacture Biopharmaceuticals In Australia

Source: AcuraBio
iStock-1179679055-brisbane-australia

World-class researchers and state-of-the-art facilities, a streamlined regulatory framework, and generous tax incentives have made Australia a prime location for the biotech industry.

Over the past decade, Australia has become a global leader in life science research and biologics manufacturing. Generous tax incentives and government funding are further strengthening its position as a prime location for biotech companies.

Placed 17th in 2010, Australia has jumped to fifth (out of 54 countries) in global biotechnology1, outperforming countries like the United Kingdom, Germany, and Canada.

Australia is home to more than 400 locally-owned biotechnology and 500 MedTech companies, and with around 50 multinationals operating subsidiaries in Australia, including GSK, Merck, Pfizer, Bristol-Myers Squibb, and Novartis, the Australian life sciences sector is valued at over AU$100 billion.

VIEW THE ARTICLE!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma